CDK4 and breast cancer: Another relevant finding of the present study is that the combination of gedatolisib with ET and/or CDK4/6 inhibitors was effective in treatment-naïve and palbociclib/fulvestrant-adapted BC cell lines with or without PIK3CA mutations.